PHARMACOSMEDICS: what changed
PHARMACOSMEDICS
Largest movements
- Receivables within one year -€14,029
down €14,029 (-19.9%), from €70,425 to €56,395
of which Other amounts receivable: -€8,005
- Cash +€13,296
up €13,296 (+481%), from €2,767 to €16,063
mainly Receivables within one year (+€14,029) and Net result for the year (+€5,183)
- Trade debts -€7,069
down €7,069 (-7.4%), from €95,693 to €88,624
- Profit (loss) carried forward +€5,183
up €5,183 (+12.6%), from -€41,090 to -€35,908
- Gross operating margin +€16,475
up €16,475, from -€5,766 to €10,709
- Other operating charges -€15,315
down €15,315 (-75.6%), from €20,255 to €4,941
- Financial charges +€271
up €271 (+86.2%), from €315 to €586
Change in the result, 2025 to 2026
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2025 and 2026 balance sheets and the 2026 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2025 | 2026 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €290,034 | €289,301 | -€733 | -0.3% |
| Fixed assets | 21/28 | €1,000 | €1,000 | = | 0.0% |
| Financial fixed assets | 28 | €1,000 | €1,000 | = | 0.0% |
| Current assets | 29/58 | €289,034 | €288,301 | -€733 | -0.3% |
| Stocks and contracts in progress | 3 | €215,760 | €215,760 | = | 0.0% |
| Stocks | 30/36 | €215,760 | €215,760 | = | 0.0% |
| Amounts receivable within one year | 40/41 | €70,425 | €56,395 | -€14,029 | -19.9% |
| Trade receivables | 40 | €17,372 | €11,348 | -€6,024 | -34.7% |
| Other amounts receivable | 41 | €53,053 | €45,048 | -€8,005 | -15.1% |
| Cash at bank and in hand | 54/58 | €2,767 | €16,063 | +€13,296 | +481% |
| Deferred charges and accrued income | 490/1 | €82 | €82 | = | 0.0% |
| Total equity and liabilities | 10/49 | €290,034 | €289,301 | -€733 | -0.3% |
| Equity | 10/15 | €88,910 | €94,092 | +€5,183 | +5.8% |
| Contributions | 10/11 | €125,000 | €125,000 | = | 0.0% |
| Contributions outside capital | 11 | €125,000 | €125,000 | = | 0.0% |
| Other | 1109/19 | €125,000 | €125,000 | = | 0.0% |
| Reserves | 13 | €5,000 | €5,000 | = | 0.0% |
| Non-distributable reserves | 130/1 | €5,000 | €5,000 | = | 0.0% |
| Reserves not available under the articles | 1311 | €5,000 | €5,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€41,090 | -€35,908 | +€5,183 | +12.6% |
| Amounts payable | 17/49 | €201,124 | €195,208 | -€5,916 | -2.9% |
| Amounts payable within one year | 42/48 | €201,099 | €195,208 | -€5,890 | -2.9% |
| Trade debts | 44 | €95,693 | €88,624 | -€7,069 | -7.4% |
| Suppliers | 440/4 | €95,693 | €88,624 | -€7,069 | -7.4% |
| Other amounts payable | 47/48 | €105,406 | €106,584 | +€1,179 | +1.1% |
| Accrued charges and deferred income | 492/3 | €26 | €0 | -€26 | -100% |
| Other operating charges | 640/8 | €20,255 | €4,941 | -€15,315 | -75.6% |
| Gross operating margin | 9900 | -€5,766 | €10,709 | +€16,475 | |
| Operating profit (loss) | 9901 | -€26,022 | €5,768 | +€31,789 | |
| Financial income | 75/76B | - | €1 | +€1 | |
| Recurring financial income | 75 | - | €1 | +€1 | |
| Financial charges | 65/66B | €315 | €586 | +€271 | +86.2% |
| Recurring financial charges | 65 | €315 | €586 | +€271 | +86.2% |
| Profit (loss) for the period before taxes | 9903 | -€26,336 | €5,183 | +€31,519 | |
| Profit (loss) for the period | 9904 | -€26,336 | €5,183 | +€31,519 | |
| Profit (loss) for the period to be appropriated | 9905 | -€26,336 | €5,183 | +€31,519 |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 March 2025 and 31 March 2026. Green is a favourable move for that line, red an unfavourable one. Prepared on 5 November 2026 via checked.be.